University of South Florida

About: University of South Florida is a education organization based out in Tampa, Florida, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 34231 authors who have published 72644 publications receiving 2538044 citations. The organization is also known as: USF.

Rectification of the Bias in the Wavelet Power Spectrum

Abstract: This paper addresses a bias problem in the estimate of wavelet power spectra for atmospheric and oceanic datasets. For a time series comprised of sine waves with the same amplitude at different frequencies the conventionally adopted wavelet method does not produce a spectrum with identical peaks, in contrast to a Fourier analysis. The wavelet power spectrum in this definition, that is, the transform coefficient squared (to within a constant factor), is equivalent to the integration of energy (in physical space) over the influence period (time scale) the series spans. Thus, a physically consistent definition of energy for the wavelet power spectrum should be the transform coefficient squared divided by the scale it associates. Such adjusted wavelet power spectrum results in a substantial improvement in the spectral estimate, allowing for a comparison of the spectral peaks across scales. The improvement is validated with an artificial time series and a real coastal sea level record. Also examined is the previous example of the wavelet analysis of the Nino-3 SST data.

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

Abstract: Background Patients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) often continue to experience symptoms despite receiving standard-of-care therapy with H 1 -antihistamines along with 1 or more add-on therapies. Objectives We sought to evaluate the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent CIU/CSU despite treatment with H 1 -antihistamines at up to 4 times the approved dose plus H 2 -antihistamines, leukotriene receptor antagonists, or both. Methods In this phase III study patients were randomized to receive 6 subcutaneous injections at 4-week intervals of either 300 mg of omalizumab or placebo, followed by a 16-week observation period. The primary objective of the study was to evaluate the overall safety of omalizumab compared with placebo. Efficacy (itch severity, hive, and urticaria activity scores) was evaluated at weeks 12 and 24. Results The overall incidence and severity of adverse events and serious adverse events were similar between omalizumab and placebo recipients; the safety profile was consistent with omalizumab in patients with allergic asthma. At week 12, the mean change from baseline in weekly itch severity score was −8.6 (95% CI, −9.3 to −7.8) in the omalizumab group compared with −4.0 (95% CI, −5.3 to −2.7) in the placebo group ( P Conclusion Omalizumab was well tolerated and reduced the signs and symptoms of CIU/CSU in patients who remained symptomatic despite the use of H 1 -antihistamines (up to 4 times the approved dose) plus H 2 -antihistamines, leukotriene receptor antagonists, or both.

Primary productivity and particle fluxes on a transect of the equator at 153°W in the Pacific Ocean

Abstract: Primary productivity (14C) and mass flux measurements using a free-drifting sediment trap deployed at 900 m were made at four stations in the Pacific Ocean between 12°N and 6°S at 153°W. The latitudinal variations in productivity were consistent with historical patterns showing the equator as a zone of high production and the oligotrophic waters north of the equatorial region as an area of low productivity. The correlation coefficient between the two sets of independent measurements was 0.999, indicating that in this oceanic area the activity of the primary producers was closely related to the total mass flux. A re-examination of historical data suggests that the downward flux of particulate organic carbon varies in direct proportion to the quotient of surface primary production raised to the 1.4 power and depth raised to the 0.63 power.

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

Abstract: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.